April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

What’s Next for Myopia Management

Consensus report provides strategies that more accurately reflect the possible severity of disease.

Conexiant

March 28, 2025

New Dosing Option for Hemophilia A and B

The FDA approved Qfitlia (fitusiran) for hemophilia A or B prophylaxis in patients aged 12 and older, offering reduced bleeding rates with bi-monthly dosing.

Conexiant

March 27, 2025

Medical Oddities: Metabolism’s Secret Sugar-Burning Switch

Science served weird this week: sleepy seniors, sneaky genes, and memory-hacking babies.

Conexiant

March 27, 2025

Hypoglycemia Cases Tied to Slush Drinks

A new study identifies glycerol intoxication syndrome in children after consuming slush ice drinks, leading to hypoglycemia, metabolic acidosis, and altered consciousness.

Conexiant

March 27, 2025

Study Finds Significant Increases in Prevalence, Severity of Astigmatism

Prolonged digital device use and reduced outdoor exposure following the COVID-19 pandemic may have contributed to the refractive changes.

Conexiant